3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
3
Carcinoma, Renal Cell
3
Virus Diseases
1
Urinary Bladder Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma in Situ
1
Adenoviridae Infections
1
Interventions
human papillomavirus vaccine, L1 type 16, 18
3
valrubicin
1
ledipasvir, sofosbuvir drug combination
1
hepatitis C immune globulin, human
1
halofantrine
1
VP-102
1
Therapies, Investigational
1
Papillomavirus Vaccines
1
Oncolytic Virotherapy
1
Mitomycin
1
Ipilimumab
1
Interferons
1
Influenza Vaccines
1
Immunoglobulin G
1
Imiquimod
1
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
1
Gemcitabine
1
Gels
1
Drug Therapy
1
Cantharidin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Virus Diseases
×
Interferons
×
Clear all
NCT01438112
2021-04-14
BOND
CG Oncology, Inc.
Phase 2/3
Terminated
22 enrolled